课题基金 / 基金详情

Targeting pancreatic cancer metastases with Targefrin

Targeting pancreatic cancer metastases with Targefrin
用 Targefrin 靶向胰腺癌转移
批准号:
10763331
负责人:
Carlo Baggio
金额:
$40.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-14 至 2024-08-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
摘要 我们打算设计一种基于名为EphA 2的特异性癌细胞受体的新型治疗策略, 在转移性胰腺癌的表面大量存在在过去的几年里,我们的研究集中在 测试靶向受体的药剂在抑制细胞迁移和侵袭中的抗癌潜力, 细胞研究以及使用体内模型抑制肿瘤转移。最近我们得到了 迄今为止报道的最有效的激动剂,其有效靶向EphA 2受体并引起其 降解在初步研究中,该试剂对抑制胰腺癌细胞有显著效果, 迁移该试剂也引起受体的内化;因此,我们打算探索我们是否可以 也可以使用这种药物选择性地对胰腺肿瘤进行化疗。
英文摘要
ABSTRACT We intend to devise a novel therapeutic strategy based on a specific cancer cell receptor named EphA2, which is abundant on the surface of metastatic pancreatic cancers. Over the past several years our studies focused on testing the anti-cancer potential of agents targeting the receptor in suppressing cell migration and invasion in cellular studies, as well as in inhibiting tumor metastases using in vivo models. Very recently we have derived the most effective agonistic agent reported to date that potently targets the EphA2 receptor and causes its degradation. In preliminary studies, the agent is remarkably effective in inhibiting pancreatic cancer cell migration. The agent also causes the internalization of the receptor; hence we intend to probe whether we can use this agent also to deliver chemotherapy selectively to pancreatic tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金